Electronic Supplementary Information

“Wash-free” synthesis of cyclodextrin metal-organic frameworks

Shuhei Fujita,* Kazunori Kadota, b Atsushi Koike, c Hiromasa Uchiyama, b
Yuichi Tozuka b and Shunsuke Tanaka*ad

a Department of Chemical, Energy and Environmental Engineering, Faculty of Environmental and Urban Engineering, Kansai University, 3-3-35 Yamate-cho, Suita-shi, Osaka 564-8680 JAPAN
b Department of Formulation Design and Pharmaceutical Technology, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka 569-1094, Japan.
c Department of Pathobiochemistry, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka 569-1094, Japan.
d Collaborate Research Center of Engineering, Medicine and Pharmacology (CEMP), Organization for Research and Development of Innovative Science and Technology (ORDIST), Kansai University, 3-3-35 Yamate-cho, Suita-shi, Osaka 564-8680 JAPAN

*E-mail: shun_tnk@kansai-u.ac.jp

Table of Contents

<table>
<thead>
<tr>
<th>Table of Contents</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Experimental Materials, Synthesis and Characterization.</td>
<td>S2–S3</td>
</tr>
<tr>
<td>Figure S1 PXRD patterns of products prepared without mechanochemical treatment.</td>
<td>S4</td>
</tr>
<tr>
<td>Figure S2 PXRD patterns of CD-MOFs prepared with different potassium sources.</td>
<td>S5</td>
</tr>
<tr>
<td>Figure S3 Thermogravimetric curves of CD-MOFs prepared using different potassium sources.</td>
<td>S6</td>
</tr>
<tr>
<td>Figure S4 N2 adsorption isotherms of CD-MOFs prepared with different potassium sources.</td>
<td>S7</td>
</tr>
<tr>
<td>Figure S5 N2 adsorption isotherm of product washed after mechanochemical treatment.</td>
<td>S8</td>
</tr>
<tr>
<td>Figure S6 FESEM images of CD-MOFs.</td>
<td>S9</td>
</tr>
<tr>
<td>Figure S7 PXRD patterns of CD-MOFs dried at 60 °C and 80 °C after mechanochemical step.</td>
<td>S10</td>
</tr>
<tr>
<td>Figure S8 PXRD patterns of CD-MOFs prepared with different ethanol/CD ratios.</td>
<td>S11</td>
</tr>
<tr>
<td>Figure S9 PXRD patterns of CD-MOFs prepared at different mechanochemical treatment times.</td>
<td>S12</td>
</tr>
<tr>
<td>Figure S10 PXRD patterns of drug-encapsulated CD-MOF.</td>
<td>S13</td>
</tr>
</tbody>
</table>
Experimental

Materials

Potassium hydrogen carbonate (KHCO₃, >99.5 %), potassium acetate (CH₃COOK, >97.0 %), potassium hydroxide (KOH, >85.0 %), potassium chloride (KCl, >99.5 %), potassium carbonate (K₂CO₃, >99.5 %), gamma-cyclodextrin (CD, >97.0 %), levofloxacin (>98.0 %), methanol (>99.5 %) and ethanol (>99.5 %) were purchased from Fujifilm Wako Pure Chemical Corporation. All chemicals were used without further purification.

Synthesis

Wash-free mechanochemical synthesis: CD and potassium source (KHCO₃, CH₃COOK, KOH, KCl or K₂CO₃) together with a small amount of ethanol were placed in a 250 ml zirconia milling jar containing 30 YTZ® balls. Typically, the molar ratio of mixture is CD : K⁺ : ethanol = 1 : 2 : 0.04; the K⁺/CD ratio can be varied from 0.67 to 8 and the ethanol/CD ratio can be reduced to 0.0085. These were then milling at a rotation rate of 150 rpm for 5 min by using planetary mill Pulverisette 6 (Fritsch Japan). The products were only dried under atmospheric pressure at 60 °C or 80 °C for 1 h.

Vapor diffusion method: CD-MOF was prepared as described by Smaldone et al.¹ with some minor modifications. 1 mmol of CD and 8 mmol of KOH were dissolved in 20 mL of deionized water. The aqueous solution was filtered with a 0.20-μm nylon membrane. The container containing the aqueous solution was placed in a container containing 50 mL of methanol and exposed to vapor diffusion at 30 °C. After 7 days, the aqueous solution containing the diffused methanol vapor was centrifuged and separated into liquid and solid phases. The product was thrice-washed with methanol. Next, the product was dried overnight and then vacuum dried at 50 °C for 6 h.

Characterization

Powder X-ray diffraction (PXRD) was performed at room temperature under atmospheric pressure using a RIGAKU MiniFlex600. CuKalpha (wavelength 0.15418 nm) was used as an X-ray tube at 30 kV and 15 mA. The BET area and pore volume were obtained by performing nitrogen adsorption/desorption measurements at the temperature of liquid nitrogen (77 K) using a MicrotracBEL BELSORP-max. Before measurements, pretreatment was performed by heating at 50 °C for 6 h in a vacuum using a MicrotracBEL BELPREP-vac. Thermogravimetric analysis was conducted using a Shimadzu Corporation DTG-60H. Approximately 5 mg of sample was placed in an alumina cell and heated from room temperature to 600 °C at a rate of 5 °C/min. Field emission scanning electron microscope (FESEM) images were recorded on a Hitachi High-Tech S-4800. The measurement was performed at an acceleration voltage of 2.0–3.0 kV. To estimate the drug content in CD-MOF, the chemical compositions of the final product were measured by using an energy-dispersive X-ray spectrometry Emax EVOlution (Horiba) and drug concentrations of the elute were measured using a UV-visible spectrophotometer UV-1900i (Shimadzu).
The cytotoxicity of the CD-MOF carriers was evaluated by the cell viability assay using MRC-5 lung fibroblast cells \((4 \times 10^5 \text{ cells/mL})\), A549 alveolar epithelial cells \((4 \times 10^5 \text{ cells/mL})\) and Caco-2 small intestine epithelial cells (confluent).\(^2^3\) MRC-5 and Caco-2 cells were cultured in Minimum Essential Medium (MEM; Sigma-Aldrich; St. Louis, MO, USA) and A549 cells were cultivated in Dulbecco’s Modified Eagle’s Medium (DMEM; Sigma-Aldrich) under 5% CO\(_2\) at 37 °C for 24 h. Each medium was supplemented with 10% (v/v) fetal calf serum, 50 U/mL penicillin, and 50 μg/mL streptomycin. The cells were treated with a dispersion of CD-MOFs at a final concentration of 0.1–10 g/L. After 24 h of treatment, cell viability was assessed using a Cell Counting Kit-8 (Dojindo Molecular Technologies, Kumamoto, Japan) according to the manufactures’ protocols. The absorbance at 450 nm was measured using a Multiskan FC microplate photometer (Thermo Fisher Scientific, Waltham, MA, USA). The cell viability (%) was calculated using the following equation:

\[
\text{cell viability(\%)} = \frac{\text{abs}_{\text{sample}}}{\text{abs}_{\text{control}}} \times 100
\]

where \(\text{abs}_{\text{sample}}\) and \(\text{abs}_{\text{control}}\) represent the absorbance with and without the addition of samples, respectively.

References


Figure S1 PXRD patterns of the products prepared without mechanochemical treatment.
Figure S2 PXRD patterns of CD-MOFs prepared with different potassium sources (KHCO₃, CH₃COOK, KOH, KCl and K₂CO₃). CD-MOFs were prepared at K⁺/CD = 2 by wash-free mechanochemical synthesis.
Figure S3 Thermogravimetric curves of CD-MOFs prepared using different potassium sources (KHCO₃, CH₃COOK, KOH and KCl). CD-MOFs were prepared at K⁺/CD = 2 by wash-free mechanochemical synthesis.
**Figure S4** N\textsubscript{2} adsorption/desorption isotherms of CD-MOFs prepared with different potassium sources (KHCO\textsubscript{3}, CH\textsubscript{3}COOK, KOH, KCl and K\textsubscript{2}CO\textsubscript{3}). Before the measurements, the samples were degassed at 50 °C under vacuum for 6 h.
Figure S5 $N_2$ adsorption/desorption isotherm of the product washed after mechanochemical treatment. The product was prepared using KHCO$_3$ at K$^+$/CD = 2. Before the measurements, the samples were degassed at 50 °C under vacuum for 6 h.
Figure S6 FESEM images of CD-MOFs prepared by (upper) conventional vapor diffusion method and (bottom) wash-free mechanochemical synthesis. CD-MOF was prepared using KHCO₃ at K⁺/CD = 2 by wash-free mechanochemical synthesis.
Figure S7 PXRD patterns of CD-MOFs prepared using KCl at $K^+/CD = 1.5$ by wash-free mechanochemical synthesis. After the mechanochemical step, the products were dried at 60 °C or 80 °C.
Figure S8 PXRD patterns of CD-MOFs prepared by wash-free mechanochemical synthesis with different ethanol/CD ratios using KCl at K⁺/CD = 1.
**Figure S9** PXRD patterns of CD-MOFs prepared at different mechanochemical treatment times. CD-MOFs were prepared using KCl or KHCO$_3$ at K$^+$/CD = 1.5.
Figure S10 PXRD patterns of CD-MOF and drug-encapsulated CD-MOF. CD-MOFs were prepared by wash-free mechanochemical synthesis using KHCO₃ at K⁺/CD = 2.